Every Form 4 that Moderna, Inc. (MRNA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MRNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRNA filings page.
Moderna, Inc. chief executive Stephane Bancel reported equity compensation activity involving company common stock. On February 11, 2026, performance-based restricted stock units granted on February 28, 2023 vested, resulting in an acquisition of 11,271 common shares at $0. On the same date, 5,450 shares were disposed of at $41.99 per share to cover tax withholding obligations related to this vesting, a non‑open‑market tax-withholding disposition. Following these transactions, Bancel directly held 6,187,791 common shares. The filing also reports indirect holdings of 9,210,686 shares through Boston Biotech Ventures and 6,564,880 shares through OCHA LLC, for which he disclaims beneficial ownership except for any pecuniary interest.
Moderna director Noubar B. Afeyan, through Flagship Pioneering, Inc., exercised stock options for 23,853 shares of Moderna common stock at $10.90 per share on December 11, 2025, and on the same day sold 23,853 shares at $29.485 per share.
After these transactions, Flagship Pioneering held 3,924 Moderna shares, while affiliated funds held 3,880,328 shares through Flagship Ventures Fund IV, L.P. and 747,897 shares through Flagship Ventures Fund IV-Rx, L.P. Afeyan also directly owned 2,224,015 shares. The options exercised were fully vested, covered 23,853 shares and had been scheduled to expire on February 23, 2026, and Afeyan disclaims beneficial ownership of the fund-held shares except to the extent of his pecuniary interest.
The Chief Executive Officer and director of Moderna, Inc. reported exercising a stock option for 688,073 shares of common stock on 12/11/2025. The option, which was fully vested and scheduled to expire on February 23, 2026, had an exercise price of $10.90 per share. The reporting person paid $7,499,995.70 for the shares and $5,998,279.76 of withholding taxes in cash, for a total of $13,498,275.46, and no shares were sold or withheld to fund the exercise. After the transaction, the reporting person beneficially owned 6,181,970 Moderna shares directly, and additional indirect holdings were reported for Boston Biotech Ventures (9,210,686 shares) and OCHA LLC (6,564,880 shares), for which beneficial ownership is disclaimed except to any pecuniary interest.
Moderna, Inc. reported that a company director sold a small block of shares in an insider transaction. On December 9, 2025, the director sold 504 shares of Moderna common stock at a price of $27.60 per share. The transaction was executed under a Rule 10b5-1 trading plan that was adopted on September 5, 2025, indicating it was pre-arranged. The sale was made to generate cash to cover the tax liability arising from the vesting of restricted stock units. Following this sale, the director beneficially owns 1,515 shares of Moderna common stock directly.